

BIO 2018 – Boston

WORKING WITH THE MEDIA

Moira Gunn, Ph.D. Bioentrepreneurship

Associate Professor, University of San Francisco

Associate Director for Bioentrepreneurship, PSM/Biotechnology

Host, *BioTech Nation*, *Tech Nation Health* & *Tech Nation*


The NPR Channel/SiriusXM, and other NPR venues



Bioentrepreneurship



BioTech
Nation



Tech Nation
npr
24-hr Pgm Stream

WORKING WITH THE MEDIA

*BIO 2018 Biotechnology Entrepreneurship
Boot Camp*


Welcome to the your
Biobusiness Media Primer !!!



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A few questions:

- Anyone here a member of the media?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A few questions:

- Anyone here a member of the media?
- Anyone a former member of the media?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A few questions:


- Anyone here a member of the media?
- Anyone a former member of the media?
- Experience dealing with the media?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A few more questions:

- Anyone here been *misrepresented* in the media?



WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A few more questions:

- Anyone here been misrepresented in the media?
- Anyone here with *a positive experience* with the media?

WORKING WITH THE MEDIA


BIO 2018 Biotechnology Entrepreneurship Boot Camp

You've just participated in ...

LESSON #1



Bioentrepreneurship



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You've just participated in ...

LESSON #1

Know Your Audience

WORKING WITH THE MEDIA


BIO 2018 Biotechnology Entrepreneurship Boot Camp

**When you are targeting journalists
and media outlets ...**

Know their Audience



Bioentrepreneurship



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Now you are ready for ...


LESSON #2



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

LESSON #2

***You Cannot Control
What the Media Reports
about You ...***

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

LESSON #2

You Cannot Control

***What the Media Reports
about You ...***

***But You Can Give Yourself
Your Best Shot***

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Caveat ...

*What I'm telling you is
my experience
being a member of
the Global Science-Business Media*

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

JOURNALIST

- Host, *Tech Nation* and its segment, **BioTech Nation** and its successor segment **Tech Nation Health** on NPR
- Author, “Welcome to BioTech Nation”
- Multiple domestic stations, airplays on NPR 24-hour program stream, NPR Sirius-XM (full nationwide + global coverage), NPR WorldSpace, AFRTS to 177 countries, et al.
- Podcasts, iTunes, Stitcher, et al.
- In the bio industry, 900++ interviews with CEOs, VCs, policymakers, elected officials, regulators, etc.
- At each BIO, 45-55 interviews



WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

PROFESSOR

- Associate Director for Bioentrepreneurship, PSM/Biotechnology
- Cross-university graduate program

Exemplar Courses

- Local, National & Global Bio-Business
- Global & US Regulatory Affairs
- Legal, Social & Ethical Implications of Biotech
- Study Tours to Global Bioclusters – London/Oxford/Cambridge, Switzerland, Wash, DC, Puerto Rico, Australia, Canada, San Diego

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

The *journalist* in me wants to tell you
HOW to deal with the media ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

The *journalist* in me wants to tell you
HOW to deal with the media ...

The *professor* in me
wants to tell you **WHY**

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

So let's start there ...

Why should a Biotech Business be concerned about Media?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception

Media drives Google-able Data

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception

Media drives Google-able Data

Media does *NOT* drive Truth

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

And ...

Perception *drives* **What You Can Do**

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


*What's the difference between Advertising
and Public Relations?*



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

*What's the difference between Advertising
and Public Relations?*

In Advertising, you say you're great

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

*What's the difference between Advertising
and Public Relations?*

In Advertising, you say you're great

*In Public Relations, somebody else says you
are great*

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

*What's the difference between Advertising
and Public Relations?*

In Advertising, you say you're great

*In Public Relations, somebody else says you
are great ... or not*

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

WHAT DO YOU NEED TO DO?

WHERE DOES MEDIA FIT ...

... in the transition from cutting-edge science
to the registered product ???

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


You need it when you are raising money ...



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You need it when you are raising money ... you
need it when you are raising money ... you need
it when you are raising money ... you need it
when you are raising money ... you need it when
you are raising money ... *you need it when you
are raising money ... you need it when you are
raising money ... you need it when you are
raising money ... you are raising*


MONEY



Bioentrepreneurship



BioTech Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH MEDIA

Traditional Target Audiences

Biobusiness Media Audiences

Venture Capitalists
Industry Analysts
Regulatory Personnel
Biotech Industry Organizations
Service Professionals
Financial Advisors
Policymakers
Legislators
Insurance Providers

Healthcare Providers
- Hospitals
- Healthcare Systems
- Individual Providers
Industry Organizations
Educators
Special Interest Groups
Consumer Advocates
Consumers

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A Frequent Source of Money ...

Venture Capitalists

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

A Frequent Source of Money ...

Venture Capitalists

Back to Lesson #1 – Know Your Audience

Who are they?

What is important to them?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

*Here's some insight into who the VC's are in the **Biopharma** space ...*

- *Sought to validate the Bioenterprise Innovation Expertise Model (BIEM 2.0) through experienced biopharma VC's*
- *An ancillary result was insight into the VC's*

*Journal of
Commercial
Biotechnology
(2016) 22(2) 50-63*

Article

The BIEM Verification Study: Experienced Venture Capitalists Assess a Biopharmaceuticals Innovation Expertise Model

Moir Gunn

Founded and directs the Business of Biotechnology Program in the School of Management at the University of San Francisco, where she is an assistant professor. The former President of SIBER, the Society for International Bioentrepreneurship Education and Research, she also hosts Tech Nation, and its regular segment BioTech Nation, which air on the NPR channel of SiriusXM, among other venues.

Nola Masterson

Is Founder and Managing Director of Science Futures Management Company, LLC, and an Adjunct Professor in the Business of Biotechnology Program in School of Management of University of San Francisco.

Paul Lorton, Jr.

Is a Professor of Management Information Systems in the School of Management at the University of San Francisco.


Jacques Baronet

Is a Professor of Entrepreneurship and Innovation Management at the University of Sherbrooke, Quebec, Canada.

ABSTRACT

Developing biopharmaceutical therapies is a scientifically complex endeavor, requiring from ten to fifteen years of effort with successive rounds of increasingly greater investment capital in a risk-intensive landscape. With failure rates at 88%, and an all-attempts-averaged investment of over \$2B per approved drug, discussions of what leads to success and/or failure are pervasive. In this milieu, the BIEM (Bioenterprise Innovation Expertise Model) model was developed so that the status of a bioenterprise could quickly be assessed. Assessing the BIEM model, 20 biopharmaceuticals venture capitalists with 30 years average biotechnology industry experience, all having board experience, most having served as board chairs, and 80% having been CEO's and/or presidents, rated the innovation expertise disciplines of BIEM 2.0 as to their importance in the scientific discovery through market-ready product innovation phase of biopharmaceutical development. Despite a small sample size, statistically significant insights were produced, verifying the BIEM model. The most important innovation expertise disciplines were intellectual property, science, regulatory expertise, and venture capital, in that order. Further, the strongest correlations linked regulatory expertise and science, and equally so, intellectual property and venture capital. Additional insights with respect to the profiles of the biopharmaceutical venture capitalists themselves is also presented.

Bioenterprise Innovation Expertise Model (BIEM 2.0)



Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

- ***20 Biopharmaceutical VCs***

- ☐ *Minimum biobusiness expertise: 20 years*
- ☐ *Average biobusiness expertise: 30 years*


- ***Validated all the BIEM disciplines***

- ☐ *Introduced/suggested no add't'l disciplines*

- ***Interrelations – Most Strongly Correlated***

- ☐ *IP with Venture Capital*
- ☐ *Regulatory Expertise with Science*
- ☐ *Technology with Information Systems*


Experienced Biopharmaceuticals Venture Capitalists' Assessment of BIEM Model Innovation Expertise



Who are the Biopharma VC's?


BIO 2018 Biotechnology Entrepreneurship Boot Camp

Experienced Biopharmaceuticals Venture Capitalists' Biotechnology Industry Career Positions Held



How do VC's Rate Their Own Expertise?

Self-Assessed Combined Primary and Secondary Expertise Profiles
Biopharmaceuticals Venture Capitalists



Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

- **No New** expertise areas were identified
- **Not All** expertise areas important at every stage
- Expertise **dynamically** needed over time
 - Every organization/effort is **unique**
- **Every** bioenterprise could need **Media Savvy** at any stage of development – from inception through to fully-delivered product

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp


You get a meeting with a VC ...



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

... you better google you beforehand

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

... you better google you beforehand

Do you have an answer for everything?

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

... you better google you beforehand

Do you have an answer for everything?

... at least you should know about the item

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

... you better google you beforehand

Do you have an answer for everything?

... at least you should know about the item

How do you play “DEFENSE” when it’s serious?

Validating BIEM 2.0

BIO 2018 Biotechnology Entrepreneurship Boot Camp

You get a meeting with a VC ...

They will google you immediately beforehand

... you better google you beforehand

Do you have an answer for everything?

... at least you should know about the item

How do you play “DEFENSE” when it’s serious?

... here’s how

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Case Study #1: Playing Defense

Date: 2015

*The Biotech Marketspace: **Oncolytic Viruses***


*Media Outlet: **Breaking Industry News***



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Amgen

Profile: Large biopharma firm, Thousand Oaks, California

Traded on NASDAQ at roughly \$164/share

2015 Revenue: \$22 Billion

Back in 2015, had a Lead Oncolytic Virus product candidate:

>>> “T-Vec” for Melanoma

>>> No others approved at the time

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Media Outlet: “*Fierce Biotech*” – fiercebiotech.com

[DDF 2017](#)

[FiercePharma](#)

[Jobs](#)

[Resources](#)

[Events](#)

[Subscribe](#)



FierceBiotech

A Division of
QUESTEX

[BIOTECH](#)

[RESEARCH](#)

[IT](#)

[CRO](#)

[MEDTECH](#)



Accelaron dumps dalantercept after kidney cancer trial fail



Lilly's CGRP inhibitor galcanezumab hits the mark in migraines



Struggling Regulus promotes ex Lilly exec as new CMO



EU, U.S. and Japanese regulators join forces on antibiotic trials



OSE, MSK ally to advance anti-CD127 NSCLC candidate

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

FierceBiotech

A publication of **FierceMarkets**

FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. [Click here](#) to get your free weekly email briefing today!

The FierceMarkets Network:

Telecom

FierceCable
FierceDeveloper
FierceWireless:Europe
FierceWirelessTech
FierceOnlineVideo
FierceTelecom
FierceWireless
FierceInstaller

Marketing & Retail

FierceCMO
FierceMobileMarketer
FierceRetail
FierceRetailIT
FierceMobileRetail

Healthcare

FierceEMR
FierceHealthcare
FierceHealthFinance
FierceHealthIT
FierceHealthPayer
FierceHealthPayerAntiFraud
FierceMobileHealthcare
FiercePracticeManagement
Hospital Impact

Government

FierceGovernment
FierceGovernmentIT
FierceHomeland Security
FierceMobileGovernment
FierceCities
FierceGovHealthIT

Life Sciences

FierceBiotechResearch
FierceBiotech
FierceBiotechIT
FierceCRO
FierceDiagnostics
FierceDrugDelivery
FierceMedicalDevices
FiercePharma
FiercePharmaAsia
FiercePharmaManufacturing
FiercePharmaMarketing
FierceVaccines
FierceAnimalHealth

Enterprise IT

FierceBigData
FierceCIO
FierceContentManagement
FierceDevOps
FierceEnterpriseCommunicatio
FierceIT Security
FierceMobileIT

Energy

FierceEnergy
SmartGridNews

Finance


FierceCFO
FierceFinanceIT



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

Back in June, 2015 ...

FierceVaccines

NEWS TOP



Hold the offer: Bavarian Nordic declares it's not for sale

Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.

Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken



TOP HE

EDITOR

Globelmr
partnerec
fails in PI

Globelmmu
vaccine for
mark in a PI
value of a p
Sciences. R
FierceBiote

Serum In
partner to
vaccine i

May 28, 2015

Serum Instil
compatriot C
market a flu

Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA

Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA advisory committee recommendation last month, Amgen rolled out its data from a pivotal study of its cancer vaccine talimogene laherparepvec (T-Vec) on Tuesday as it awaits the agency's final decision, expected later this year.

REGISTER TODAY!



THE LIBRARY: WEBINAR

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp



SHERLOCK HOLMES

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp



SHERLOCK HOLMES



“You see, but you do not observe.
The distinction is clear.”

Sherlock Holmes
A Scandal in Bohemia
by Sir Arthur Conan Doyle



Back in June, 2015 ...

FierceVaccines

NEWS TOP



Hold the offer: Bavarian Nordic declares it's not for sale

Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.

Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken



TOP HE

EDITOR

Globelmr
partnerec
fails in PI

Globelmmu
vaccine for
mark in a PI
value of a p
Sciences. R
FierceBiote

Serum In
partner to
vaccine i

May 28, 2015

Serum Instil
compatriot C
market a flu

Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA

Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA advisory committee recommendation last month, Amgen rolled out its data from a pivotal study of its cancer vaccine talimogene laherparepvec (T-Vec) on Tuesday as it awaits the agency's final decision, expected later this year.

REGISTER TODAY!



THE LIBRARY: WEBINAR

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Typical Media Scenario

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **FDA** issues final decision

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Typical Media Scenario

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **FDA** issues final decision

THIS MEDIA SCENARIO ???

Press announcement #1 **FDA panel** issues positive decision

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Typical Media Scenario

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **FDA** issues final decision

THIS MEDIA SCENARIO ???

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **Amgen publishes pivotal T-Vec data**
as it awaits FDA decision

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Typical Media Scenario

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **FDA** issues final decision

THIS MEDIA SCENARIO ???

Press announcement #1 **FDA panel** issues positive decision

Press announcement #2 **Amgen publishes pivotal T-Vec data**
as it awaits FDA decision

What's this item about?
And WHY???

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


So I entered “T-Vec” in the FierceBiotechSearch Box ...



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

Results of “T-Vec” search in FierceBiotech ...

Amgen publishes pivotal T-Vec data as it awaits FDA decision

➡ FierceVaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Without this new Amgen story, if anyone entered “T-Vec” in the Search Box, the **first thing** to pop up would be ...

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Without this new Amgen story, if anyone entered “T-Vec” in the Search Box, the **first thing** to pop up would be ...

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

... and this story has **nothing to do** with T-Vec

Amgen publishes pivotal T-Vec data as it awaits FDA decision

➔ FierceVaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

Might Amgen have strategically pushed the “Suicide stunner” headline down by intentionally creating a new story?

Prior to the “Suicide Stunner” Story, Amgen Consistent Positive/ Non-problematic Mentions In FierceBiotech

NewLink continues cancer vaccine Ph III trial with interim data under wraps

 [FierceVaccines](#) | May 14, 2015

with Bristol-Myers Squibb's (\$BMJ) Yervoy, and Amgen (\$AMGN), which is testing its T-Vec with Merck's ...

Profound reverse-merges onto T SX; Startup wins €2M to develop novel dialysis tech;

 [FierceMedicalDevices](#) | May 1, 2015

@JohnCFierce: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes ...

Omnicare draws buyout interest from Express Scripts, CVS; Akorn asks Oklahoma not to use its drugs to execute;

 [FiercePharma](#) | May 1, 2015

next big M&A splash. Articles | Follow @FierceBiotech @JohnCFierce: T-Vec panel demonstrates just ...

An EEG via a tattoo?; Samsung testing Alzheimer's memory app;

 [FierceMedicalDevices](#) | April 30, 2015

wins FDA panel nod for T-Vec in melanoma. News > Final trial results show GSK malaria vaccine's ...

Report: Pfizer bids on Sobi; Bellicum buys into TCR;

April 30, 2015

than Merck's Zostavax in older adults, study says. Story > Amgen wins FDA panel nod for T-Vec ...

Celgene sales miss, profits double; Opdivo closes in on first-line melanoma use;

 [FiercePharma](#) | April 30, 2015

Merck's Zostavax in older adults, study says. Story > Amgen wins FDA panel nod for T-Vec in melanoma. ...

Amgen wins FDA panel nod for T-Vec in melanoma

 [FierceVaccines](#) | April 29, 2015

submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing Amgen is gunning for approval ...

By the next day, the headlines were already moving again ...

UPDATED: Bristol-Myers dominates--and disappoints--at ASCO immuno-oncology debut

May 29, 2015

Laboratories. Related Articles: FDA panel gives a thumbs up to Amgen's T-Vec for melanoma Bristol-Myers ...

Amgen publishes pivotal T-Vec data as it awaits FDA decision

👉 FierceVaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

LESSON #156

*If there is any inadvertent
“negative perception”,
create a new (and different!) story
to push it down*

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Case Study #2: Let's Play Some More Defense

The Tyranny of

INDUSTRY REPORTS

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

The perception of the biocluster in which you operate can affect the perception of your company, your R&D, and your investment potential

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

The perception of the biocluster in which you operate can affect the perception of your company, your R&D, and your investment potential

- **#1 - Negative** media coverage wrt your biocluster can adversely affect you

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

The perception of the biocluster in which you operate can affect the perception of your company, your R&D, and your investment potential

- **#1 - Negative** media coverage wrt your biocluster can adversely affect you
- **#2 - Untrue** negative press coverage even more so

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Some judge success potential and investment potential of bioclusters by ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Some judge success potential and investment potential of bioclusters by ...

#1 – number of **patents** applied for/issued

#2 – number of high-impact **peer-reviewed journal articles** created by biocluster organizations

#3 – amount of **recent investment dollars**

#4 – number of **start-ups**

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

We'll look at two bioclusters

Hong Kong
Puerto Rico

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

HONG KONG

Profile: Life Science Industry – Pharmaceuticals, Traditional Chinese Medicines, Medical Devices and Biotechnology

250-300 biotech-related companies

70 listed on Hong Kong Stock Exchange

*“The total number of basic medical publications per year was doubled to about **700** between 1997 – 2002. It is estimated that Hong Kong universities produce about **250** biomedical publications of high impact factor per annum at present.”* **Hong Kong Innovation and Technology Commission, April 12, 2017**

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Puerto Rico

**Profile: Life Science Industry – Pharmaceuticals,
Medical Devices and Biotechnology**

Pharmaceuticals - \$40B/year

7 of top 10 drugs manufactured there

12 of top 20 pharma/biopharma companies there

49 FDA-approved manufacturing plants

Medical Devices - \$4B/year

7 of top 10 drugs manufactured there

12 of top 20 medical device companies there

78 medical device manufacturing plants

*Until recently, Univ of PR life science researchers prevented from profiting
from their research breakthroughs – hence, few start-ups*

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Hong Kong & Puerto Rico

Neither are Nation-States per the United Nations

PR – U.S. Territory

HK – Autonomous Territory of China

But what does this matter?

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


*Let's look at **INDUSTRY REPORTS***



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Scientific American WorldVIEW +++ ScoreCard

www.saworldview.com



WORKING

BIO 2018 Biotechnology Entrepreneurship

2015

Scientific American WorldVIEW Scorecard

“Author! Author!
The highest ranked nations
publish the most”

AUTHOR! AUTHOR!

The highest-ranked nations publish the most

As a meta-analysis, the *Scientific American* Worldview Scorecard is created from a broad collection of data comparisons. This year we added a new resource to this mix, the Nature Index (<http://www.natureindex.com/>), which tracks scientific publications. In past issues we've examined the connection between a nation's rank on the Scorecard and its publishing output, and the Index allows us to revisit that concept—but with data from a far greater number of countries. Our results show that several nations in particular generate many more publications than might be expected.

The Nature Index not only provides a database of scientific publications but it also keeps track of the institutional and country affiliations of each author. It divides articles in four main categories: chemistry, earth and environmental sciences, life sciences and physical sciences. Data for each country are collected by article count (AC), with each nation receiving a credit for any article in which it can claim one of the authors. The database also calculates a weighted

fractional count (WFC), which indicates the percentage of authorship from a country (and includes an adjustment that addresses an imbalance in some of the journals being tracked).

For each country, we compare the Nature Index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Hong Kong and Puerto Rico, which are not in the Nature Index). Not surprisingly, the results show considerable scatter, especially since some segments of the life sciences do not relate to biotechnology. Likewise, other categories of the Nature Index, such as chemistry, include articles that would impact aspects of biotechnology. Nonetheless, the graph shows that a higher overall Scorecard finish is associated with a higher article output. In fact, the findings suggest a potentially exponential correlation.

Certain countries score much higher than expected. For example, the U.S. WFC lands nearly off the chart—more than four times greater than predicted by the correlation equation that best fits the data. China also exceeded expectations, publishing far more articles than other nations finishing as low as it does on the Scorecard. As we've noted in the past, however, publishing lots of articles is not the same as publishing lots of valuable articles.



WORKING

BIO 2018 Biotechnology Entrepreneurship

2015

Scientific American

WorldVIEW Scorecard

“For each country, we compare the Nature Index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Hong Kong and Puerto Rico, which are not in the Nature Index.)”

AUTHOR! AUTHOR!

The highest-ranked nations publish the most


As a meta-analysis, the Scientific American Worldview Scorecard is created from a broad collection of data comparisons. This year we added a new resource to this mix, the Nature Index (<http://www.natureindex.com/>), which tracks scientific publications. In past issues we've examined the connection between a nation's rank on the Scorecard and its publishing output, and the Index allows us to revisit that concept—but with data from a far greater number of countries. Our results show that several nations in particular generate many more publications than might be expected.

The Nature Index not only provides a database of scientific publications but it also keeps track of the institutional and country affiliations of each author. It divides articles in four main categories: chemistry, earth and environmental sciences, life sciences and physical sciences. Data for each country are collected by article count (AC), with each nation receiving a credit

fractional count (WFC), which indicates the percentage of authorship from a country (and includes an adjustment that addresses an imbalance in some of the journals being tracked).

For each country, we compare the Nature Index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Hong Kong and Puerto Rico, which are not in the Nature Index). Not surprisingly, the results show considerable scatter, especially since some segments of the life sciences do not relate to biotechnology. Likewise, other categories of the Nature Index, such as chemistry, include articles that would impact aspects of biotechnology. Nonetheless, the graph shows that a higher overall Scorecard finish is associated with a higher article output. In fact, the findings suggest a potentially exponential correlation.

Certain countries score much higher than expected. For example, the U.S. WFC lands nearly off the chart—more than four times



WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


Let's look in the NATURE Index ...



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Let's look in the NATURE Index ...

“404 Page not found”

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

PUERTO RICO ... is not a country

HONG KONG ... is not a country

- But its universities and research institutions – and their publications – are separately listed in the Nature Index
- If you scrape that data, the picture changes



If Hong Kong & Puerto Rico had been included...

USA
7,606

2,000

1,000

CHINA

PUERTO RICO #31

HONG KONG #11

SCIENTIFIC AMERICAN WORLDVIEW SCORE

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Puerto Rico & Hong Kong


Inadvertently marginalized and misrepresented in these two respected industry reports



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Puerto Rico & Hong Kong

*Inadvertently **marginalized and misrepresented** in these two respected industry reports*

Also, Puerto Rico has mainstream media problems

#1 – \$70 Billion debt + \$50 Billion pension obligations

#2 – The Zika virus

#3 – loss of government-provided economic advantages

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Case Study #3: When the News is Really Bad

Falling Out of Phase 3

WORKING WITH THE MEDIA



[ABOUT US](#)

[PIPELINE](#)

[INVESTORS](#)

[NEWS](#)

NOVAVAX' TECHNOLOGY PLATFORM


The Novavax technology platform produces two different types of immunogenic particles that form the basis of our vaccines: virus-like particles (or VLPs) and recombinant protein micelles.



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA



[ABOUT US](#)

[PIPELINE](#)

[INVESTORS](#)

[NEWS](#)

RESPIRATORY SYNCYTIAL VIRUS


RSV causes infections of the lower respiratory tract and acutely impacts infants, the very young, the elderly and others with compromised immune systems.



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

NOVAVAX

Creating Tomorrow's Vaccines Today

[ABOUT US](#)

[PIPELINE](#)

[INVESTORS](#)

[NEWS](#)

MATERNAL IMMUNIZATION


With no available therapy, full-term infants would greatly benefit from a vaccine to protect them from RSV.



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

 [View printer-friendly version](#)

[<< Back](#)

Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults

- Topline data from the Resolve™ Phase 3 trial did not meet pre-specified efficacy objectives
 - The attack rate for the Phase 3 primary objective was approximately 25% of that observed in Phase 2 trial
- Topline data from our Phase 2 rollover trial suggest improved vaccine efficacy from a second year of dosing

Management will host a conference call at 5:00 pm ET time today

GAITHERSBURG, Md., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The Resolve™ trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy. Consistent with our previous clinical experience, the vaccine was well tolerated.

WORKING WITH THE MEDIA

Topline efficacy results of the trial are shown in the following table:

Summary of Primary and Secondary Objectives – Vaccine Efficacy				
	Number of Participants - ITT Population (11,856)			
Primary and Secondary Objectives	Placebo (5,935)	Vaccine (5,921)	Vaccine Efficacy (CI)	P-Value
Primary: RSV msLRTD, N(%)	26 (0.44%)	28 (0.47%)	-7.9 % (-84, 37)	0.78
Secondary: RSV ARD, N(%)	117 (1.97%)	102 (1.72%)	12.6 % (-14, 33)	0.32

“We are both surprised and disappointed by the outcome of the Resolve trial, which we recently unblinded. Our initial analyses and review of the key aspects of the trial do not indicate issues with trial execution, data collection, data integrity, or drug product quality. We expect to have preliminary immunogenicity data in the coming weeks to further our understanding of the trial results,” said Gregory Glenn M.D., President, Research and Development. “Historically, annual seasonal RSV ARD attack rates between 3% and 7% have been observed in older adults¹. In our Phase 2 trial, we observed an RSV ARD attack rate of 4.9% and an RSV msLRTD attack rate of 1.8%. In contrast, we observed an RSV ARD attack rate of 2.0% and an msLRTD attack rate of 0.4% in our Phase 3 trial. These attack rates indicate a mild RSV season in older adults this year. We are continuing to investigate potential root causes that could have impacted the outcome of this trial. We continue to believe that there is a path forward for our RSV vaccine and that there is an important unmet need for an RSV vaccine in older adults.”

Novavax, Inc.

NASDAQ: NVAX - Sep 27, 6:53 PM EDT

2.28 USD ↓0.07 (2.98%)

After-hours: 2.27 ↓0.44%

1 day

5 day

1 month

3 month

1 year

5 year

max



Open 2.43
High 2.47
Low 2.14

Mkt cap 649.94M
P/E ratio -
Div yield -

Novavax, Inc.

NASDAQ: NVAX - Sep 27, 6:53 PM EDT

2.28 USD ↓0.07 (2.98%)

After-hours: 2.27 ↓0.44%

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

1.72 -0.01 (-0.58%)

At close: 18 May 4:00PM EDT

nth

1 year

5 year

max

⊕ Indicators ⊕ Comparison 📅 Date range 1D 5D 1M 3M 6M YTD 1Y 2Y **5Y** Max 📅 Interval 1W ▾ 📈 Line ▾ 🖨 Draw

⚙ Set

NVAX 1.9700



WORKING WITH THE MEDIA

BIO 2014 Bio-Entrepreneurship Boot Camp

No matter what, the **POINT** of *Strategic Media* is to

...

Reach essential **TARGET AUDIENCES**

WHEN you need to reach them

WORKING WITH MEDIA

BIO 2018? – Can get pre-registered Media Lists

24	Alex	Keown	Freelance Journalist	BioSpace	IA		1 8177	keown.a	Yes
25	Harry	Tracy	Editor and Publisher	NeuroPerspective	CA		1 7607	neuro@r	Yes
26	Jennifer	Boggs	Managing Editor	BioWorld Today	GA		1 7708	jennifer.	Yes
27	Ken	Stone	Contributing editor	Times of San Diego	CA		1 6192	kens@ti	Yes
28	Lisa	Lamotta	Editor	Informa Life Sciences Group	DC		1 9085	llamotta	Yes
29	Beth	Kutscher	Healthcare news editor	Modern Healthcare	CA		1 4158	bkutsche	Yes
30	Ron	Leuty	Biotech reporter	San Francisco Business Times	CA		1 4152	rleuty@	Yes
31	Katelyn	Busse	Scientist	Biotech Weekly	CA		1 6092	katelyn@	Yes
32	Johann	Tsai	Journalist	Global Bio & Investment Monthly		Taiwan	8862 2	johann.t	Yes
33	Karen	Pihl-Carey	Analyst	BioWorld Today	PA		1 7708	karen.pil	Yes
34	Joshua	Berlin	Executive Editor	BioCentury Inc.	CA		1 6505	jberlin@	Yes
35	Donald	Zuhn	Editor	Patent Docs	IL		1 3129	zuhn@m	Yes
36	Owen	Hughes	Senior Editor	UC Technology Journal	CA		1 5307	uctechjo	Yes
37	Marie	Powers	News Editor	BioWorld Today	GA		1 7704	marie.pc	Yes
38	Laura	Helbling	Senior Writer	The Pink Sheet/Informa	DC		1 5738	laura.hel	Yes
39	Wayne	Koberstein	Executive Editor	Life Science Leader	OR		1 5415	wayne.k	Yes
40	Tamra	Sami	International business journa	Pharmasia News	Western / Australia		61 04 5	T.Sami@	Yes
41	Karen	Jagoda	Host and Producer	Empowered Patient Podcast	CA		1 8586	kjagoda@	Yes
42	Kim	Walpole	Producer	Empowered Patient Podcast	CA		1 5184	kim@tri	Yes
43	Anne	Montgomery	Editor in Chief	BioProcess International	OR		1 5416	amontgc	Yes
44	Jim	Miller	Editor	Advanstar Communications, Inc	VA		1 7033	jim.mille	Yes
45	James	Cavuto	Editor	Neurotech Business Report	CA		1 4155	editorial	Yes
46	Lisa	Melton	Senior News Editor	Nature Biotechnology		United Kir	44 20 7	l.melton	Yes,n

WORKING WITH MEDIA


Best Way to reach Traditional Journalists:

One-on-One Relationships

... but you still need press releases and marketing materials ... **NO MISSPELLINGS**

WORKING WITH MEDIA

Should you hire a public relations professional?



WORKING WITH MEDIA

Should you hire a public relations professional?

- Good Idea!

-

-

WORKING WITH MEDIA

Should you hire a public relations professional?

- Good Idea!
- With good relationships with the media
-

WORKING WITH MEDIA

Should you hire a public relations professional?

- Good Idea!
- With good relationships with the media
- Who will help connect **YOU** so you can cultivate relationships with the media directly

WORKING WITH MEDIA

One more kicker ...

- *Professional business journalists preferred source of reliable – and quoted – information is ... the CEO*
 - *Highest ranking of preferred sources: 36% (Messner, et al.)*

WORKING WITH MEDIA

Other ways to get in front of journalists

- Work with industry organizations –
 - BIO and its regional counterparts
- Work with press offices at professional conferences you attend – anyone know where the press room is here at BIO?

WORKING WITH MEDIA

Now let's quickly look at the difference
between dealing with Traditional Media
and dealing with Social Media ...

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp

Target Audiences

*can be reached **BY PROXY** through*

TRADITIONAL MEDIA

*can be reached **DIRECTLY** through*

SOCIAL MEDIA

WORKING WITH MEDIA

In addition, the bioenterprise can use Social Media proactively to create and influence communities ...

Genomic Health's --

Facebook/YouTube/Twitter campaign:

“Pass It On ... Until Every Woman Knows”

WORKING WITH MEDIA

***For *ALL* Media ...
... there are challenges***

WORKING WITH MEDIA

First Challenge

You need to describe both the
Business Proposition **AND** Science

WORKING WITH MEDIA

Second Challenge

ETHICAL PERSUASION

*Getting Accurate and Persuasive
INFORMATION OUT,
While Correcting **MISINFORMATION***

WORKING WITH MEDIA

Rules for Journalists

Know Your Journalist

WORKING WITH MEDIA

Rules for Journalists

What's everybody's favorite subject?

WORKING WITH MEDIA

Rules for Journalists

What's everybody's favorite subject?
Themselves **

*** True also for journalists ...*

WORKING WITH MEDIA

Rules for Journalists

***What's everybody's 2nd favorite
subject?***

... Humans

WORKING WITH MEDIA

Rules for Journalists

***Every Journalist needs
a different story***

WORKING WITH MEDIA

Rules for Journalists

***Constantly re-vitalize
your story/stories***

WORKING WITH MEDIA

“KALEIDOSCOPE” YOUR STORIES



WORKING WITH MEDIA

Rules for Journalists

***Come back next time
with a NEW story***

WORKING WITH MEDIA

Rules for Journalists

Tell the Truth **

***** (Tell your Truth)***

WORKING WITH MEDIA

Table 5: The TARES Test: Five principles of ethical persuasion²⁶

Truthfulness (of the message)

Authenticity (of the persuader)

Respect (for the persuadee)

Equity (of the personal appeal)

Social Responsibility (for the common good)

WORKING WITH MEDIA

Rules for Journalists

***Have people that
journalists can talk to ... *****

***** CEO, scientists, ...***

WORKING WITH MEDIA

Rules for Journalists

Be open about the competition

Be respectful about the competition

Be accurate about the competition

WORKING WITH MEDIA

Rules for Journalists

**Listen to what the journalist
tells you he or she is interested in**

WORKING WITH MEDIA

Rules for Journalists

**Never ask the journalist
to do any work**

WORKING WITH MEDIA

Rules for Journalists

**Always return
the journalist's call**

WORKING WITH MEDIA

Rules for Journalists

Even if you have nothing to say

WORKING WITH MEDIA

Rules for Journalists

Especially if you have nothing to say

WORKING WITH MEDIA

Rules for Journalists

You can never control the story

WORKING WITH MEDIA

Last Rule for Journalists

It's not just who you know ...

It's who, who you know, knows

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


Thank You !!!



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

WORKING WITH THE MEDIA

BIO 2018 Biotechnology Entrepreneurship Boot Camp


QUESTIONS ...



Bioentrepreneurship



BioTech
Nation



Tech Nation
n p r
24-hr Pgm Stream

BIO 2018 – Boston

WORKING WITH THE MEDIA

Moira Gunn, Ph.D.

Associate Professor, University of San Francisco

Associate Director for Bioentrepreneurship, PSM/Biotechnology

Host, *BioTech Nation*, *Tech Nation Health* & *Tech Nation*


The NPR Channel/SiriusXM, and other NPR venues



Bioentrepreneurship



BioTech
Nation



Tech Nation
npr
24-hr Pgm Stream